65 related articles for article (PubMed ID: 38612815)
41. Nodal stage migration and prognosis in anal cancer: a systematic review, meta-regression, and simulation study.
Sekhar H; Zwahlen M; Trelle S; Malcomson L; Kochhar R; Saunders MP; Sperrin M; van Herk M; Sebag-Montefiore D; Egger M; Renehan AG
Lancet Oncol; 2017 Oct; 18(10):1348-1359. PubMed ID: 28802802
[TBL] [Abstract][Full Text] [Related]
42. Association of ctDNA detection and recurrence assessment in patients with neoadjuvant treatment.
Zhou J; Mo H; Hu D; Zhao X; Zhou H; Pan J
Cancer Med; 2023 Oct; 12(19):19794-19806. PubMed ID: 37746916
[TBL] [Abstract][Full Text] [Related]
43. Optimal management of squamous cell carcinoma of the anal canal: where are we now?
Eng C; Ahmed S
Expert Rev Anticancer Ther; 2014 Aug; 14(8):877-86. PubMed ID: 24981728
[TBL] [Abstract][Full Text] [Related]
44. Circulating tumor DNA as a Predictive and Prognostic Biomarker in the Perioperative Treatment of Muscle-invasive Bladder Cancer: A Systematic Review.
Crupi E; de Padua TC; Marandino L; Raggi D; Dyrskjøt L; Spiess PE; Sonpavde GP; Kamat AM; Necchi A
Eur Urol Oncol; 2024 Feb; 7(1):44-52. PubMed ID: 37330413
[TBL] [Abstract][Full Text] [Related]
45. Clinical Utility of Analyzing Circulating Tumor DNA in Patients with Metastatic Colorectal Cancer.
Nakamura Y; Yoshino T
Oncologist; 2018 Nov; 23(11):1310-1318. PubMed ID: 29700206
[TBL] [Abstract][Full Text] [Related]
46. The future of circulating tumor DNA as a biomarker in HPV related oropharyngeal squamous cell carcinoma.
Haring CT; Dermody SM; Yalamanchi P; Kang SY; Old MO; Chad Brenner J; Spector ME; Rocco JW
Oral Oncol; 2022 Mar; 126():105776. PubMed ID: 35183912
[TBL] [Abstract][Full Text] [Related]
47. Impact of Circulating Tumor DNA-Based Detection of Molecular Residual Disease on the Conduct and Design of Clinical Trials for Solid Tumors.
Kasi PM; Fehringer G; Taniguchi H; Starling N; Nakamura Y; Kotani D; Powles T; Li BT; Pusztai L; Aushev VN; Kalashnikova E; Sharma S; Malhotra M; Demko ZP; Aleshin A; Rodriguez A; Billings PR; Grothey A; Taieb J; Cunningham D; Yoshino T; Kopetz S
JCO Precis Oncol; 2022 Mar; 6():e2100181. PubMed ID: 35263168
[TBL] [Abstract][Full Text] [Related]
48. Circulating Tumour DNA as Biomarker for Colorectal Liver Metastases: A Systematic Review and Meta-Analysis.
Wullaert L; van Rees JM; Martens JWM; Verheul HMW; Grünhagen DJ; Wilting SM; Verhoef C
Cells; 2023 Oct; 12(21):. PubMed ID: 37947598
[TBL] [Abstract][Full Text] [Related]
49. Prognostic value of ctDNA detection in patients with early breast cancer undergoing neoadjuvant therapy: A systematic review and meta-analysis.
Papakonstantinou A; Gonzalez NS; Pimentel I; Suñol A; Zamora E; Ortiz C; Espinosa-Bravo M; Peg V; Vivancos A; Saura C; Villacampa G; Oliveira M
Cancer Treat Rev; 2022 Mar; 104():102362. PubMed ID: 35219090
[TBL] [Abstract][Full Text] [Related]
50. Anal squamous cell carcinoma: an evolution in disease and management.
Osborne MC; Maykel J; Johnson EK; Steele SR
World J Gastroenterol; 2014 Sep; 20(36):13052-9. PubMed ID: 25278699
[TBL] [Abstract][Full Text] [Related]
51. Circulating Tumor DNA in the Immediate Postoperative Setting.
Efthymiou V; Queenan N; Haas M; Naegele S; Goss D; Faden DL
Ann Surg Oncol; 2024 Apr; 31(4):2319-2325. PubMed ID: 38190058
[TBL] [Abstract][Full Text] [Related]
52. Longitudinal ctDNA profiling in precision oncology and immunο-oncology.
Filis P; Kyrochristos I; Korakaki E; Baltagiannis EG; Thanos D; Roukos DH
Drug Discov Today; 2023 Apr; 28(4):103540. PubMed ID: 36822363
[TBL] [Abstract][Full Text] [Related]
53. [Squamous cell anal carcinoma. What's next ?].
Kim S; Spehner L; Cabel L; Bidard FC; Borg C
Bull Cancer; 2021 Jan; 108(1):80-89. PubMed ID: 33423780
[TBL] [Abstract][Full Text] [Related]
54. Circulating Tumor DNA in Precision Oncology and Its Applications in Colorectal Cancer.
Arisi MF; Dotan E; Fernandez SV
Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457259
[TBL] [Abstract][Full Text] [Related]
55. Circulating tumour DNA in B-cell lymphomas: current state and future prospects.
Lakhotia R; Roschewski M
Br J Haematol; 2021 Jun; 193(5):867-881. PubMed ID: 33550600
[TBL] [Abstract][Full Text] [Related]
56. Circulating tumor DNA (ctDNA) to evaluate minimal residual disease (MRD), treatment response, and posttreatment prognosis in pancreatic adenocarcinoma.
Ueberroth BE; Jones JC; Bekaii-Saab TS
Pancreatology; 2022 Sep; 22(6):741-748. PubMed ID: 35725696
[TBL] [Abstract][Full Text] [Related]
57. Making the Rounds: Exploring the Role of Circulating Tumor DNA (ctDNA) in Non-Small Cell Lung Cancer.
Shields MD; Chen K; Dutcher G; Patel I; Pellini B
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012272
[TBL] [Abstract][Full Text] [Related]
58. Clinical value of ctDNA in upper-GI cancers: A systematic review and meta-analysis.
Creemers A; Krausz S; Strijker M; van der Wel MJ; Soer EC; Reinten RJ; Besselink MG; Wilmink JW; van de Vijver MJ; van Noesel CJM; Verheij J; Meijer SL; Dijk F; Bijlsma MF; van Oijen MGH; van Laarhoven HWM
Biochim Biophys Acta Rev Cancer; 2017 Dec; 1868(2):394-403. PubMed ID: 28801248
[TBL] [Abstract][Full Text] [Related]
59. Prognostic utility of preoperative and postoperative KRAS-mutated circulating tumor DNA (ctDNA) in resected pancreatic ductal adenocarcinoma: A systematic review and meta-analysis.
Alqahtani A; Alloghbi A; Coffin P; Yin C; Mukherji R; Weinberg BA
Surg Oncol; 2023 Dec; 51():102007. PubMed ID: 37852124
[TBL] [Abstract][Full Text] [Related]
60. Utilizing circulating tumour DNA in radiation oncology.
Rostami A; Bratman SV
Radiother Oncol; 2017 Sep; 124(3):357-364. PubMed ID: 28735685
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]